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Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most prevalent cause of liver disease worldwide and afflicts
adults and children as currently associated with obesity and insulin resistance. Even though lately some advances have been made
to elucidate the mechanism and causes of the disease much remains unknown about NAFLD.The aim of this paper is to discuss the
present knowledge regarding the pathogenesis of the disease aiming at the initial steps of NAFLD development, when inflammation
impinges on fat liver deposition. At this stage, the Kupffer cells attain a prominent role. This knowledge becomes subsequently
relevant for the development of future diagnostic, prevention, and therapeutic options for the management of NAFLD.
1. Introduction
We are facing a rampant epidemic of nonalcoholic fatty liver
disease (NAFLD) which afflicts adults and children and is
frequently associated with obesity and insulin resistance.
In Europe and in the United States, it is estimated that 3
out of 10 adults developed NAFLD [1, 2]. As NAFLD is
mostly asymptomatic, such estimates have a high degree of
uncertainty. For example, European data suggest thatNAFLD
prevalence can fall in a wide range, between 2 and 44%
in the general population, and is present in 42.6–69.5%
of people with type 2 diabetes [3]. NAFLD prevalence in
obese children was found to reach values as high as 36–44%
regardless of the diagnostic criteria. A study that evaluate
children in the Japanese population observed that fatty liver
may occur in children as young as 6 years of age and is
directly related to the degree of obesity and specifically to
the abdominal subcutaneous fat thickness [4]. Remarkably,
women with history of gestational diabetes have a greater
prevalence of NAFLD and prospective studies estimate that
these women are at a higher risk of developing diabetes
[5]. Another group that presents high prevalence of fatty
liver is the elderly representing a public health concern for
developed countries with aged populations. The Rotterdam
study describes that NAFLD was present in more than
one-third of the assessed elderly with a sturdy association
with dysglycemia, dyslipidemia, and abdominal fat [6]. More
interestingly, the subjects with advanced age show a decrease
incidence of NAFLD suggesting the possibility of positive
selection of elderly without NAFLD [6].
The estimation of NAFLD impact at population level
poses two questions. (1) Realistically, should we assess
NAFLD recurrently in the population? (2) Is there a good,
easy, and not costly way of doing it? At a first glance,
NAFLD could be seen as a response mechanism to deal
with increased amounts of lipids intake, representing a
protective mechanism. To identify the disease in early stages,
we would need liver biopsies, the recognized gold standard
for NAFLD diagnosis. Obviously, the invasive nature of such
procedure excludes its widespread use.Themore widely used
ultrasound, however, will not inform us of the grade of liver
inflammation. Magnetic resonance imaging and computed
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tomography even though more sensitive are expensive and
cannot distinguish between simple steatosis and the severe
form ofNAFLD termed nonalcoholic steatohepatitis (NASH)
[7]. Alternatively, several indexes composed of physical and
biochemical parameters such as the fatty liver index (FLI)
have been proposed to evaluate NAFLD at the population
level [8]. Undesirably, such methods do not detail the degree
of fat neither the grade of inflammation in the liver. In
this scenario, NAFLD evaluation calls for novel biomarkers
that reflect relevant NAFLD physiopathology mechanisms
providing a solid basis for diagnosis and possible innovative
therapeutic approaches.
2. Ectopic Accumulation of Triglycerides,
Hepatic Steatosis
Triglycerides (TG) accumulation is an efficient energy storage
mechanism. When compared to carbohydrates (4,5 kcal/g)
or proteins (4 kcal/g), TG provides higher caloric intake
(9 kcal/g) [9]. As so, it is advantageous for the organism to
convert carbohydrates and amino acids into TG to be stored
in adipose tissue, in order to be used in times of fasting or
prolonged exercise [10].
Physiologically, TG are a way of balanced energy storage.
However, over the last decades, the excessive consumption of
food rich in fat and sugars, associated with excessive caloric
intake, has led to alterations in lipids and glucosemetabolism.
The current recommendations for adults are that 20% to
35% of the daily calories ingested are derived from dietary
lipids. Nevertheless, this value is estimated to be around 40%
in western diets [11]. The imbalance in lipids metabolism
is tightly associated with several diseases such as obesity,
diabetes, and NAFLD [12], representing an emerging health
concern.
Overconsumption of fat and sugar ends up in ectopic
lipids accumulation, with the liver being one of the prime
targets in this process. Hepatic accumulation results from a
disparity between lipids availability (from circulating lipid
uptake and/or de novo lipogenesis (DNL)) and lipid disposal
(via fatty acid oxidation and/or production VLDL) in the
liver [10, 13, 14]. This lipid deposition within hepatocytes
is described as hepatic steatosis and it has been suggested
to occur due to three main factors: (1) TG coming from
lipolysis of adipose tissue; (2) TG synthetized fromDNL; and
(3) TG from diet; with each one contributing about 59%,
26%, and 15%, respectively, to TG accumulation [15]. The
overflow of free fatty acids (FFAs) coming from lipolysis of
adipose tissue is the main contributor to hepatic steatosis
[15, 16]. Exacerbated accumulation of fat in the adipose tissue
culminates in adipocyte hypertrophy with limitations to
lipid storage and recruitment and activation of inflammatory
mediators [10, 14].
Hepatic steatosis occurs primarily by the formation of
lipid droplets [17] considered to be a noncytotoxic structure
of TG storage [10]. Lipid droplets of TG have a protective
effect against lipids deposition, preventing the formation
of toxic lipids intermediates [18]. Conversely, FFA coming
from circulation, per se, may be toxic to hepatocytes, since
they are able to stimulate innate immune system receptors,
such as toll-like receptors (TLRs) [19], contributing to the
inflammatory response. In addition, FFA may also impact
differently on hepatocytes, depending on their nature and
not specifically on their quantity. Other studies have shown
that the ratio of monounsaturated fatty acids (MUFA) to
saturated fatty acids (SFA) determines whether liver cells
are damaged by FFA flux [20]. In vitro experiments also
demonstrated that incubation with palmitate (SFA) lead to
cell toxicity, with ROS production and cell death, contrary to
incubation with oleate (MUFA). Oleate alone increased TG
accumulation without cell damage and in combination with
palmitate and promoted lipid droplet formation abolishing
the palmitate effect [21]. Another study showed that increased
levels of stearoyl-CoA desaturase-1 (SCD1), the enzyme that
catalyzes the desaturation of SFA palmitate to the MUFA
oleate, protects from cell death in the context of FFA overflow
[20]. Similar results have been observed in animal models of
progressive liver disease, where SCD1 expression was highly
suppressed with consequent decrease in esterification of SFA
into TG, thus promoting liver injury [20, 22].
The exactmechanisms bywhich SFA-induced lipotoxicity
occur are not well established. It is known that these FFA
promote the release of several proinflammatory cytokines
and trigger endoplasmic reticulum (ER) and oxidative stress
[23]. ER is responsible for an adequate protein synthesis,
folding, and secretion and its disruption may compromise
cell viability. Excessive SFA entering hepatocytes are con-
ducted to the formation of saturated phospholipids that are
then integrated into ER membrane bilayers, affecting ER
membrane fluidity [24].Therefore, the process responsible for
degrading misfolded proteins, the unfolded protein response
(UPR), is activated, culminating in apoptosis when the
number of unfolded proteins cannot be processed [25].
Increased oxidative stress was observed inNASHpatients
and in animal model in association with accumulation of
oxidized lipids [26]. Taken together, evidences show that SFA
have a huge impact on hepatocytes viability. High fat and high
carbohydrate diets have a vast SFA component, with higher
SFA/MUFA ratio, which is critical to NAFLD progression.
Highlighting the role of diet composition, it was shown
that NAFLD and NASH patients had a dietary intake richer
in SFA and cholesterol and poorer in polyunsaturated FFA
and fibers [27]. A lower intake of proteins and zinc was also
shown in these patients [28].
3. The Role of Carbohydrates
Evidence suggests that high sugar intake combined with
lipid oversupply exacerbates liver pathology. Fructose is a
popular monosaccharide used industrially in the form of
high-fructose corn syrup (45% glucose; 55% fructose) to
sweeten foods and beverages [29]. Consumption of fructose
has markedly increased and is estimated to be 2-3 times
greater in patients with NAFLD, compared with patients with
other liver diseases or healthy control individuals [30, 31].
In humans, all fructose that is ingested is metabolized
by the liver [32]. In contrast to hepatic glucose, fructose is
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neither converted into glycogen nor stimulates postprandial
ghrelin or insulin secretion, failing to initiate the central sati-
ety response [33]. Moreover, this carbohydrate was reported
to stimulate hepatic DNL through increasing the expres-
sion of two transcription factors, sterol regulatory element-
binding protein-1c (SREBP-1c) and carbohydrate-responsive
element-binding protein (ChREBP), that regulate the activity
of lipogenic enzymes [34]. Comparison of fructose and
glucose intake in human studies revealed that the first is more
lipogenic than the later (10% versus 2% increase in DNL)
[35]. A recent study suggested that fructose consumption
may specifically promote lipid deposition in visceral adipose
tissue, particularly in men, whereas glucose consumption
appears to favor subcutaneous adiposity [36].
Fructose per se plays a role in triggering inflammation,
possibly through the disruption in gut microbiota and
increased mucosal permeability. Spruss et al. [37] showed
that mice exposed to fructose exhibited markedly intestinal
bacterial overgrowth and increased intestinal permeability,
leading to an endotoxin-dependent activation of hepatic
Kupffer cells (KCs). Increased plasma concentration of tumor
necrosis factor (TNF)-𝛼, portal lipopolysaccharide (LPS),
and myeloid differentiation primary response gene (MyD)88
have observed these mice [37].
Taken together, these results show fructose as an impor-
tant dietary contributor to NAFLD pathogenesis and severity
[38], being more detrimental than other carbohydrates.
4. Nonalcoholic Steatohepatitis and the
Multiple Hit Hypothesis
The severe form of NAFLD disease is termed as NASH and is
characterized by the presence of hepatocellular injury, lobular
and/or portal inflammation, and frequently, deposition of
collagen fibers [39]. Although patients with steatosis are
at increased risk of progressing to severe forms of liver
disease, NASH may develop in absence or in presence of
very little steatosis [39]. This indicates that steatosis and
inflammationmay not always be sequential events.The initial
view that considered steatosis as a primary hit and gut-
derived endotoxin as the second hit determining progression
of the disease is now followed by a more complex model
where many hits may act in parallel [40]. Dysregulation in
lipid metabolism associated with diet-induced changes in
microbiota and increased proinflammatory signaling to the
liver together with the liver local inflammatory response is
amongst the hits involved in NASH [40]. In light of this
model, hepatic inflammation may be either the cause or
consequence of steatosis, but it is always determinant in
tipping the balance towards NASH and worse prognosis.
5. The Gut/Adipose Tissue/Liver Axis
Recent evidences place the liver and its local response to
metabolic and immune mediated disturbances in the gut-
adipose tissue axis [41]. Understanding how this interplay is
disturbed in NASH constitutes the current challenge. Cer-
tain dietary factors may promote lipotoxicity and/or induce
alterations in the gut microbiota that may result in abnormal
activation of the gut immune response and bacterial product
translocation with systemic impact on immune system mod-
ulation [42]. It was observed that mice deficient in inflam-
masomes, which are cytoplasmic multiprotein complexes
that sense endogenous or exogenous pathogen-associated
molecular patterns (PAMPs) or damage-associated molec-
ular patterns (DAMPs), showed perturbations in intesti-
nal microbiota. When placed under methionine-choline-
deficient (MCD) diet for 4 weeks, known to cause similar
features of human NASH, the inflammasome deficient mice
developed severe symptoms like a marked impairment in
glucose homeostasis, increased weight gain, and NASH
development that could be transferred to wild-type cohoused
mice. These experiments clearly associate changes in micro-
biota with NAFLD development and obesity [41]. In support,
high levels of endotoxin in circulation have been associated
with NAFLD development in both human andmouse studies
[43]. Disturbances in nutrient absorption are other suggested
potential adverse effects of gut microbiota imbalances [40,
44]. Complex carbohydrates can be fermented by certain
gut bacteria and converted into short-chain fatty acids that
stimulate DNL [43]. Adipose tissue dysfunction in its turn
is highly linked to the development of hepatic steatosis.
Excessive adiposity leads to insulin resistance, augmented
lipolysis, increase FFA circulation, and secretion of inflam-
matory mediators that promote liver steatosis and organ
inflammation [10, 45].
6. Main Inflammatory Mediators
6.1. The Innate Immune Receptors. The innate immune sys-
tem recognizes immunogenic signals through pattern recog-
nition receptors (PRRs). Bacterial products such as LPS,
lipoproteins, flagellins, and peptidoglycans are amongst the
PAMPs recognized by these receptors. Endogenous DAMPs
like heat shock proteins, highmobility group box 1 (HMGB1),
and breakdown products of extracellular matrix liberated
from tissue damage and cell death also signal through
PRRs [46]. PRRs have been implicated in the pathophys-
iology underlying NASH. TLRs and in particular TLR4
that recognizes LPS from gram-negative bacteria and TLR9
that recognizes bacteria-derived CpG-containing DNA have
been proven critical for several aspects of disease [47, 48].
Nucleotide oligomerization domain- (NOD-) like receptors
(NLRs) are intracellular PRRs that are part of the inflam-
masomes briefly mentioned above. Inflammasomes are mul-
tiprotein complexes that through NLRs sense intracellular
danger signals and initiate an activation cascade of events that
culminate with autoactivation of caspase 1 and cleavage of
prointerleukin- (IL-) 1𝛽 and proIL-18 into mature forms [42].
By controlling the release of these important inflammatory
cytokines, Inflammasomes play an important role in the
inflammatory process underlying NASH.
TLR signaling and inflammatory cytokines like IL-1
regulate the activation of the transcription factor NF-𝜅B, a
critical modulator of liver immune responses [49].
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6.2. TLR4, TLR9, and Inflammasomes. TLRs are found in
several cellular components like plasma membrane and
endosomes and the majority associates with a common
adaptor molecule, MyD88 through Toll/IL-1 receptor (TIR)
domain. Trafficking and location of TLRs within the cell
are important for ligand binding and downstream signaling
transduction. TLR4 is located mainly in the plasma mem-
brane and associates with the LPS binding protein CD14
and myeloid differentiation- (MD)-2 molecule to recognize
LPS. TLR4 can also bind to TIR-domain containing adapter
inducing interferon-𝛽 (TRIF) to induce type 1 interferon
(IFN) throughMyd88 independent pathway [50]. Endosomal
TLR4 seems to recruit preferentially TRIF while plasma
membrane TLR4 recruits MyD88 and engages MAP kinases
and NF-𝜅B signaling [51]. Amelioration of steatosis and
NASH achieved by TLR4 deficiency in several diet-induced
mouse models of NAFLD has placed this molecule at the
center of inflammation driven pathology [37, 43, 48, 52, 53].
Expression of proinflammatory cytokines is suppressed in
TLR4 knockoutmice underNAFLDprone conditioning [43].
Increased LPS translocation into portal vein is thought to
activate the liver resident macrophages, the KCs, inducing
the production of inflammatory cytokines and type 1 IFN,
contributing to leukocyte infiltration and fibrogenesis [50].
Markedly, wild-type mice on chow diet when infused con-
tinuously with low-dose LPS developed hepatic steatosis,
insulin resistance, and weight gain [54]. TLR4, while mostly
expressed on KCs, is also found on other liver cells like hepa-
tocytes and hepatic stellate cells (HSCs), the main producers
of extracellularmatrix in the fibrotic liver. Interestingly, TLR4
expression on HSC was critical to sensitize these cells to
profibrogenic tumor growth factor (TGF𝛽) signaling in a
Myd88 dependent path in a model of hepatic fibrosis [52].
TLR4 was also important for HSCs mediated recruitment
of KCs. TGF𝛽 secretion by KCs is required for fibrosis
development. However, absence of TLR4 on KCs did not
affect the fibrogenic process in this model [52].
TLR9 is located in the endosomal compartment and
binds to an unmethylated CpG motif that is very prevalent
in bacterial DNA. TLR9 knockout mice under a choline-
deficient amino acid defined (CDAA) diet for 22 weeks,
known to induce NASH with characteristic steatosis, inflam-
mation, and fibrosis, showed amelioration of disease through
suppression of IL-1𝛽 secretion by KCs [55]. These results link
TLR9 signalling to inflammasome activation.
The most studied inflammasome is NLRP3 (also desig-
nated by NALP3 and cryporin) that comprises the NOD-like
receptor NLRP3, the apoptosis-associated speck-like protein
containing a caspase recruitment domain (Asc), and the
effector molecule procaspase 1. Inflammasome activation is
regarded as a two-step process in which the first signal,
frequently TLR signaling, upregulates inflammasome expres-
sion and the second signal triggered by an inflammasome
ligand results in activation [42]. LPS, DNA, SFA, amyloid,
cholesterol, cathepsin 𝛽, and reactive oxygen species (ROS)
among others have been suggested as NLPR3 activators.
Danger signals released from fatty acid-treated hepatocytes
were also shown to induce inflammasome activation in
liver mononuclear cells [42, 47]. Asc knockout mice showed
exacerbated MCD-induced NASH driven by abnormal gut
microbiota and increased translocation of TLR ligands into
the portal vein [41]. On the other hand, high fat feeding in
mice lacking Asc resulted in diminished weigh gain, fat mass,
and improved insulin resistance [56, 57], discrepancies that
could be attributed to heterogeneities in intestinal microbiota
[41]. Another study showed increased NLPR3 and caspase
1 expression in the liver of NASH patients [58]. Augmented
levels of these molecules in adipose tissue are also correlated
with type 2 diabetes in obese patients [59]. It is important
to note that inflammasome activation might lead to different
outcomes according to the tissue or cell-type that receives the
stimuli [42].
6.3. IL-1, TNF𝛼, and IL-6. High fat diets in mice lead to
increased hepatic expression of NF-𝜅B, hepatic steatosis, and
rise in IL-6, IL-1𝛽, and TNF𝛼 gene expression [39].
Supporting a role for inflammasome in NASH, IL-1
receptor (IL-1R), IL-1𝛽, and IL-1𝛼 knockout mice showed
attenuation of liver pathology induced by high fat diets [42].
Activation of IL-1R by IL-1 resulted in the activation of the
transcription factor NF-𝜅B [49]. IL-1 forms an autoregulatory
loop as it induces both the expression of its own precur-
sors and inflammasome components, suggesting that small
increases in this cytokine might have significant biological
effects [42].
TNF𝛼 overexpression is viewed as the hallmark of inflam-
mation in obesity and NAFLD pathology and a major link
to insulin resistance. Upon binding to its receptor, TNF𝛼
can activate proapoptotic or antiapoptotic signaling cascades
leading to NF-𝜅B activation, thus regulating cell viability,
inflammation, metabolism, and other cytokine productions
[39]. It is overproduced in adipose and muscle tissues of
obese humans and in rodent models of obesity. TNF𝛼
or TNF𝛼 receptor knockout obese mice have improved
insulin sensitivity compared to wild-type controls [60].
TNF𝛼, through NF-𝜅B both promotes and is activated by
insulin resistance and is involved in liver inflammatory and
metabolic alterations [39]. Additionally, TNF𝛼 antagonizes
the anti-inflammatory cytokine adiponectin. Adiponectin
is produced by adipocytes and sensitizes cells to insulin.
It also promotes fatty acid oxidation with marked anti-
inflammatory and antilipogenic effects in the liver [39].
Increased levels of circulating TNF𝛼, on the other hand,
correlate with NAFLD disease activity as measured by his-
tological parameters in NAFLD patients. Likewise, TNF𝛼
and TNF𝛼 receptor gene expression was increased in hepatic
and adipose tissues in NASH patients [50]. Experimental
models of insulin resistance demonstrated amelioration of
inflammation, increased insulin sensitivity, and improved
steatosis upon treatment with infliximab, a potent TNF𝛼
neutralizingmonoclonal antibody.However, highlighting the
complexity of inflammatory signaling, infliximab treatment
did not improve insulin sensitivity in human obese insulin
resistant individuals. Furthermore, pentoxifylline, a phos-
phodiesterase inhibitor, prevented TNF𝛼 production with
only modest amelioration of insulin resistance in small
studies of NASH patients [50].
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Visceral adipose tissue of obese individuals secretes
increased amounts of IL-6 when compared to subcutaneous
fat. Increased levels of plasma IL-6 were associated with
augmented inflammation and fibrosis in NAFLD patients
[39]. Adipocyte-derived IL-6 was shown to regulate hepatic
insulin resistance via upregulation of suppressor of cytokine
signaling 3 (SOCS3) which in turn induces an increase in
SREBP-1c and DNL [50].
Interestingly, IL-6 and TNF𝛼 deficient mice displayed
reduced hepatocarcinogenesis after high fat diet and upon
carcinogenesis induction by diethylnitrosamine (DEN) treat-
ment [61]. On the other hand, IL-6 deficiency was associated
with increased hepatocyte injury and apoptosis in a mouse
model of liver fibrosis [62]. In this model, IL-6 production by
nonparenchymal cells was protective possibly by downregu-
lating HSC activation [62].
7. Kupffer Cells
The liver is structurally and functionally heterogeneous.
Parenchymal cells, that is, hepatocytes, are the most numer-
ous and comprise 60% of the total liver cells and 80% of
the volume of liver. Nonparenchymal cells (NPCs) repre-
sent around 20% of the liver cells and include sinusoidal
endothelial cells (20% of liver cells), KCs (approximately
15% of liver cells), and hepatic stellate cells (5–8% of liver
cells). Other immune cell populations mostly of natural
killer T cells (NKTs) comprise a minor fraction of NPCs
[63]. Hepatocytes perform the majority of liver functions.
Nevertheless, evidence shows that both, under normal and
pathological conditions, substances released from neighbor-
ing NPCs, mainly KCs, regulate several hepatocyte functions
[64].
KCs are the resident macrophages of the liver comprising
the largest tissue specific population of macrophages in the
body. The major immune function of KCs in healthy liver
is to phagocyte and present pathogens entering from portal
vein and arterial circulation, constituting one of the first
lines of defense of the organism. Under these circumstances,
they present mostly a “tolerogenic” phenotype preventing
undesirable immune responses to the common gut-derived
antigens they are constantly in contact with [65].
KCs are differently distributed in the liver and it is
possible to find two different populations regarding its
localization. Large KCs are localized in the periportal zone
and have increased phagocytosis and increased production
of biological mediators. These large KCs can be identified
by the expression of CD163, a scavenger receptor. KCs can
be also identified by the general macrophage marker F4/80
or by CD68, which is present in all KCs regardless of their
location [65]. The KC population can be replenished by bone
marrow-derived monocytes [66]. Whether these recruited
cells form a fully independent population when compared
to liver self-renewed macrophages of fetal origin is still
debatable. In addition, macrophages present a wide range of
phenotypic and functional plasticity depending on the envi-
ronmental stimuli they perceive [67]. Classical activation of
macrophages with IFN-𝛾 and LPS induce differentiation into
the M1 phenotype marked by the release of proinflammatory
cytokines like TNF-𝛼, IL-1, and IL-12. Alternative activation
intoM2 phenotype ismore heterogeneous as different stimuli
(such as IL-4 or IL-10) can induce different phenotypes.
Typically, increased expression of arginase 1, secretion of
immune-modulatory cytokines (such as IL-10, TGF-𝛽), and
involvement in tissue repair phase are considered as indica-
tors of M2 differentiation. The different origin of the cells
together with the functional plasticity of macrophages can
explain the phenotypic and functional heterogeneity of KCs
observed upon different triggers of liver pathology.
7.1. Kupffer Cells in NAFLD. KCs are known to be involved
in the control of inflammatory responses in NAFLD. In
the early stages of the disease, hepatic macrophages expand
rapidly and secrete cytokines and chemokines such as IL-
1𝛽, TNF𝛼, CCL2, and CCL5, contributing to a paracrine
activation of protective or apoptotic signaling pathways in
hepatocytes and the recruitment of other immune cells [68].
TLR4 plays a pivotal role in KCs activation. Dietary factors,
such as fructose, may contribute to altered intestinal motility,
bacterial overgrowth, and increased intestinal permeability
which is also associated with NAFLD [67].
KCs are not only responsive to inflammatory signals
but also to metabolic fluctuations (Figure 1). As referred
previously, lipids per se and high-energy diets can be harmful
to the liver. Evidences show that overload of lipids and
cholesterol derivatives activate KCs in models of fatty liver
disease and steatohepatitis [68]. A different study also showed
that, under a high fat diet or upon FFA treatment, KCs are
activated producing high levels of proinflammatory cytokines
such as TNF𝛼 and IFN𝛾 [69] (Figure 1). In this same study,
increased levels of TLR4 were found in KCs. These results
are in accordance with another study [70] where depletion
of KCs protected against the development of high fat or high
sucrose-induced steatosis. Furthermore, in a mouse model of
steatohepatitis, mice with KCs derived fromMyD88−/− bone
marrow donors had improved inflammation and steatosis
phenotype [55]. Interestingly, KCs frommice exposed to high
fat diet were shown to accumulate increased amount of free
cholesterol and diacylglycerol. In vitro assays demonstrated
that these fat-ladenKCsweremore responsive to LPS induced
activation when compared to KCs from lean mice [68].
Accordingly, in vitro stimulation of mouse KCs with the SFA
palmitic acid was shown to upregulate expression of TLR
receptors [71]. Thus, FFA sensing by KCs may condition its
responsiveness to proinflammatory triggers.
Insulin resistance is a predominant feature in NAFLD
patients. Insulin signaling plays a critical role in modulating
both glucose and lipid metabolism. Inflammatory mediators
such as TNF𝛼 and IL-6 are highly associated with the devel-
opment of insulin resistance in the setting of obesity. In mice,
inactivation of NF-𝜅B mediated signaling, through specific
deletion of ikk𝛽 in macrophages, was shown to impair the
development of systemic insulin resistance under high fat
diet. Nevertheless, adiposity was similar in macrophage ikk𝛽
deficientmice andwild-type controls under high fat diet [72].
Similar observations were obtained in bonemarrow chimeric
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Figure 1: Kupffer cells and inflammation in NAFLD. Kupffer cells integrate a multitude of systemic and local stimuli, namely, inflammatory
cues from diet-derived alterations in gut microbiota, as well as adipose tissue and hepatocytes signals of lipid metabolism impairments.
Subsequent activation of Kupffer cells promotes a local inflammatory milieu that results in exacerbation of steatosis, hepatocyte dysfunction,
and fibrogenesis. High-energy diets induce alterations in gut microbiome and increased permeability that result in augmented passage of
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) to the portal vein. PAMPs interact with Kupffer cells
through pattern recognition receptors (PRRs), activating innate immunity signal pathways (e.g., Myd88 or inflammasome) leading to the
secretion of proinflammatory and profibrogenic cytokines. Increased adiposity and inflammation in adipose tissue caused by high-energy
diets induce the release of free fatty acids (FFAs) and adipokines into circulation. FFAs and adipokines may on one hand contribute to
Kupffer cell stimulation and on the other hand promote hepatic steatosis through enhanced FFAuptake and/or increase in de novo lipogenesis.
Additionally, cytokine release by Kupffer cells sustain hepatic stellate cell differentiation into collagen producingmyofibroblast and contribute
to hepatocyte metabolic dysfunctions.
mice where JNK1 signaling was disrupted in hematopoietic
cells [73].
7.2. Kupffer Cells and Hepatic Stellate Cells: The Path to Fibro-
sis. Liver fibrosis arises from dysregulation in the wound
healing process elicited to dampen hepatocyte damage and
is characterized by excessive matrix synthesis and altered
matrix degradation. Fibrosis occurs as progressive liver
accumulation of proteoglycans, glycoproteins, and collagens
with predominance of types I and III fibrillar collagens
and failure of physiological mechanisms of matrix turnover.
Ultimately, the fibrotic process culminates in cirrhosis with
distorted hepatic architecture associated with regenerating
hepatocyte nodules surrounded by fibrotic septa and marked
impairments in hepatic vascularization [74]. Development
of hepatocellular carcinoma occurs in about one-third of
individuals with cirrhosis [75]. Nevertheless, reversion of
advanced fibrosis and even cirrhosis is possible and has been
documented [74].
Myofibroblast thatmigrate and accumulate at sites of liver
injury in response to autocrine and paracrine signals pro-
duced by neighboring cells constitute the cellular source of
fibrosis during chronic liver diseases [74]. Although they are
heterogeneous in composition a great part of myofibroblasts
develop from liver resident HSC. HSCs are mesenchymal
cells that comprise 5–8% of total liver cells. Their prime
location is in the space of Disse between endothelial cells
and hepatic epithelial cells. In quiescent state, HSCs store
large amounts of Vitamin A in lipid droplets and can
be identified by expression of desmin and glial fibrillary
acidic protein (GFAP) [76]. Upon liver injury, HSCs sense
hepatocyte damage and immune cell signaling and respond
by transdifferentiation into activemyofibroblast-like cells that
express alpha-smooth muscle actin (𝛼-SMA) and migrate
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Figure 2: Role of Kupffer cells in fibrosis regression. Initial activation of Kupffer cells contributes to liver injury and hepatocyte cell death
through the release of inflammatory cytokines (1). Phagocytosis of hepatocyte debris, however, may trigger an an antifibrogenic phenotype in
Kupffer cells by inducing the expression of metalloproteinases that degrade collagen fibers (2). Phagocytosis may also increase Wnt signaling
in KC and promote the differentiation of hepatic progenitor cells into new hepatocytes (3). A reduced phagocytic capacity of Kupffer cells
may underlie impairments in antifibrogenic responses and contribute to the setting of fibrosis in NASH.
to sites of injury. Besides secreting extracellular matrix pro-
teins, HSCs secrete cytokines, growth factors that promote
regeneration of hepatic epithelial cells, and angiogenic factors
that modulate endothelial cell and hepatocyte proliferation.
Prolonged activation of HSC causes fibrosis and during
fibrosis regression the number of these cells is greatly reduced
by induction of cellular senescence and apoptosis and return
to quiescent state [76].
Genes regulating hepatocellular apoptosis and/or necro-
sis, genes regulating the inflammatory response to injury
(TLR4, TNF𝛼, IL-1𝛽, and IL-6), genesmediatingROS genera-
tion, and genes coding for fibrogenic growth factors (TGF𝛽1),
vasoactive substances, and adipokines (Leptin) were shown
to be critically involved in liver fibrogenesis [47, 77]. In
particular TGF𝛽1 polymorphismmay confer susceptibility to
NASH progression to fibrosis [77]. TGF𝛽 signaling in HSC
stimulates activation, synthesis of extracellular matrix pro-
tein, and inhibition of its degradation [74]. KCs secrete TGF𝛽
and platelet derived growth factor (PDGF) that constitutes
a potent mitogenic factor for HSC [47, 77] (Figure 1). Addi-
tionally, KCs through the secretion of IL-1 and TNF𝛼 lead to
activation ofNF-𝜅B signaling pathway inHSCpromoting cell
survival [78]. Interestingly, contact-independent coculture of
KCs with HSC influenced gene expression in HSC turning
the overall mRNA expression pattern more similar to what
was observed in HSC isolated from in vivomouse models of
fibrosis. Among these genes were the NF-𝜅B-regulated genes
Il-6, and tissue inhibitor of metalloproteinase 1 (timp1) [78].
Timp1 inhibitsmetalloproteinases (Mmps) that are able to cut
collagen fibers and together modulate matrix degradation.
Expression of both Timps and Mmps is tightly regulated
according to activation of HSC in regular response to liver
injury [74].
Macrophages can produce Mmps and contribute in a
later stage of the wound healing process to fibrosis regression
[79] (Figure 2). In a well described carbon tetrachloride
model of reversible murine hepatic fibrosis, macrophage
depletion during fibrosis acute phase leads to impaired acti-
vation of HSC and reduced scaring, while depletion during
recovery phase reduced matrix degradation and fibrosis
resolution [80]. In a similar mouse model of reversible
fibrosis, monocytes were recruited into the liver where they
were highly proinflammatory in initial stages, but upon
stimuli of local microenvironment they differentiated into
metalloproteinases producing macrophages necessary for
fibrosis resolution [81]. Interestingly, phagocytosis of cellular
debris was shown to trigger the phenotype switch, inducing
expression of matrix degradation associated genes (Mmp9,
Mmp12, and insulin growth factor 1) [81] (Figure 2).
Autophagy is a catabolic mechanism whereby unneces-
sary or dysfunctional cellular components are degraded in the
lysosome. Autophagy-related (ATG) genes are necessary for
the formation of the phagophore and autophagosomes, the
initial steps in autophagy [82]. Autophagy in macrophages
is critical for phagocytic functions. In a mouse model of
fibrosis, inhibition of the autophagic gene Atg5 specifically
in myeloid cells resulted in increased susceptibility to liver
inflammation and liver injury, increased secretion of IL-1,
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enhanced monocyte recruitment, and increased hepatocyte
apoptosis [82].
Phagocytosis of hepatocyte debris by liver macrophages/
KCs was also shown to promote Wnt signaling upregulation.
Wnt/𝛽-catenin signalling is crucial for hepatic progenitor cell
(HPC) differentiation and engagement into hepatocellular
fate. Macrophage depletion during hepatocyte regeneration
was shown to remove the stimuli for hepatocyte differentia-
tion andHPCdifferentiated preferentially into cholangiocyte,
forming biliary structures [83].
Macrophage plasticity may differ according to the nature
of the stimuli leading to pathology. It is unknown whether
impairments on macrophage phagocytosis and differenti-
ation into matrix degrading prone-macrophages underlie
fibrosis or hepatocellular differentiation triggered by NASH
(Figure 2).Of note, impairment inKCs phagocytosis has been
observed in high fat and high cholesterol diet-inducedmouse
models of NAFLD [84].
8. Conclusions
NAFLD is a rising concern that goes together with the
increasing prevalence and incidence of obesity being a cur-
rent epidemic problem. NAFLD pathogenesis is linked with
insulin resistance, adipose tissue distribution, and dietary and
genetic factors, which are risk factors not only for NASH but
also for diabetes and associated pathologies.
From this review, it is clear that much remains to be
understood regarding the mechanism of the disease. The
lack of knowledge in relation to this pathogenesis becomes
a hurdle in the path towards novel approaches for the
prevention and treatment of the disease. Up to our days,
prevention can only be based on calorie restriction and
favorable dietary composition as well as exercise. More
effective lifestyles/therapeutic methods should be addressed
not only to prevent fat deposition, but primarily to avoid sub-
clinical inflammation, where KCs play a prominent role. How
the interdependent effects of diet microbiota inflammation
directly impact liver dysmetabolism is an issue that remains
to be elucidated. Nevertheless, from an interventional stand-
point, this vicious cycle needs to be broken. If this hypothesis
is proven to be correct, we should start to integrate the
impact on intestinal microbiota composition and subsequent
inflammatory responses in the nutritional value of foods, as
a proxy for predicting the potential to evoke dysmetabolic
states that are determinants of NAFLD development.
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